NIAID VRC NUCLEIC ACID AND LIPID TECHNOLOGY DEVELOPMENT

NIAID的使命和范围包括通过研究、开发和临床试验新出现和地方性传染病的疫苗和疗法，对传染病暴发作出快速反应。2019年，为应对COVID-19疫情，mRNA疫苗迅速开发并进行临床评估，最终导致用于预防COVID-19的2种疫苗获得FDA许可。这种快速反应的一部分包括快速制造核酸（DNA和RNA），以支持试剂和疫苗的制造和测试，这将可用于多种传染病，如艾滋病毒，冠状病毒，流感，RSV等疾病。 此外，开发的LNP制剂将支持用于多种传染病的mRNA-LNP包封的疫苗，包括但不限于HIV、CoV、流感，并且获得临床可用的脂质纳米颗粒（LNP）制剂将使得能够低风险地加速疫苗制剂对人类使用的安全性。

The NIAID mission and scope includes rapidly responding to infectious disease outbreaks through research, development, and clinical testing of vaccines and therapeutics for emerging and endemic infectious diseases. In 2019, in response to the COVID-19 outbreak, mRNA vaccines were quickly developed and evaluated clinically, leading to the eventual FDA-licensure of 2 vaccines used in the prevention of COVID 19. Part of that quick response included rapid manufacturing of nucleic acid (DNA and RNA) to support reagent and vaccine manufacturing and testing, which would be amendable for multiple infectious diseases such as HIV, CoV, Influenza, RSV, among other diseases. Additionally, the LNP formulations developed would support mRNA-LNP encapsulated vaccines for multiple infectious diseases, including but not limited to HIV, CoV, Influenza, and access to clinically available lipid nanoparticle (LNP) formulations would enable low risk acceleration of vaccine formulations safe for human use.